Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Palbociclib · Ibrance, PD-0332991

Small molecule · Inhibitor of cyclin-dependent kinase 4 (CDK4) and cyclin-dependent kinase 6 (CDK6) · developed by Pfizer

Approved FDA, Feb 2015
PFE Developer
1 Registered trials

What is Palbociclib?

Palbociclib is a kinase inhibitor of cyclin-dependent kinases CDK4 and CDK6, which blocks progression of cells from the G1 into the S phase of the cell cycle. It acts on Rb phosphorylation and E2F signaling in hormone receptor-positive breast cancer. It is also being studied in HPV-unrelated head and neck squamous cell carcinoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Ibrance, PD-0332991
Drug type
Small molecule
Targets
cyclin-dependent kinase 4 (CDK4), cyclin-dependent kinase 6 (CDK6)
Mechanism
Inhibitor of cyclin-dependent kinase 4 (CDK4) and cyclin-dependent kinase 6 (CDK6)
Pathways
cell cycle G1 to S phase progression, Rb phosphorylation and E2F signaling, cellular senescence
Therapy area
Oncology
Developer
Pfizer (PFE)
FDA status
Approved as Ibrance (February 3, 2015), NDA207103 · FDA label
UNII
G9ZF61LE7G

✅ FDA-approved uses

From the indications section of the FDA label (version of Jul 6, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04966481 Phase 3 HPV-unrelated Head and Neck Squamous Cell Carcinoma Recruiting PFE

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

HPV-unrelated Head and Neck Squamous Cell Carcinoma

Other drugs acting on CDK4 / CDK6

More from Pfizer

Sources

Updated Nov 15, 2026. Something wrong or missing? Report it on the PFE page.

Follow PFE, the company behind Palbociclib

See PFE's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

PFE catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.